Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$256K Buy
4,076
+72
+2% +$5.01K ﹤0.01% 1257
2025
Q4
$266K Sell
4,004
-70
-2% -$4.53K ﹤0.01% 1125
2025
Q3
$274K Sell
4,074
-353
-8% -$27.9K ﹤0.01% 1089
2025
Q2
$386K Buy
4,427
+23
+0.5% +$1.8K 0.01% 626
2025
Q1
$301K Buy
+4,404
New +$359K 0.01% 608

Other funds holding DXCM

Summit Financial's DXCM Position: Q1 2026 in Review

Summit Financial increased its DexCom (DXCM) stake by 1.8% in Q1 2026, buying an estimated $5.01K and bringing the position to 4,076 shares worth $256K. The position accounts for ﹤0.01% of the portfolio, ranked #1257.

Summit Financial first reported a position in DXCM in Q1 2025 and has held it in 5 quarters since. The position peaked at $386K in Q2 2025. 957 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • Summit Financial held 4,076 shares of DexCom worth $256K as of Q1 2026.
  • Summit Financial bought 72 DexCom shares in Q1 2026, an estimated $5.01K.
  • DexCom made up ﹤0.01% of Summit Financial's portfolio in Q1 2026, its #1257 holding.
  • Summit Financial first reported a position in DexCom in Q1 2025 and has held it in 5 quarters since.
  • Summit Financial's DexCom position peaked at $386K in Q2 2025.
  • 957 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Summit Financial's 13F filing for Q1 2026, filed 15 May 2026.